Tests RZ-001 with valganciclovir in adults with glioblastoma
Tests RZ-001 plus valganciclovir in adults with glioblastoma.
Key facts
- Who runs it
- Rznomics, Inc.
- Where
- Incheon, Seongnam-si, and Seoul, South KoreaSee the 6 sites
- Trial code
- Registry title
- A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 43 people, planned
- Started
- 8 Oct 2024
- Expected to end
- May 2029
- Type of study
- Interventional, 6 groups
- Treatments tested
- RZ-001
- VGCV
- Record updated
- 5 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a confirmed grade 4 brain tumour called glioblastoma (GBM) whose tumour shows hTERT. They would receive RZ-001 together with valganciclovir.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Grade 4 astrocytoma or glioblastoma (GBM), confirmed under the microscope per the 2021 WHO Classification of CNS Tumors. Life expectancy of at least 3 months.
- Biomarker or test result
- hTERT positive expression, confirmed during screening
Main reasons for not taking part
- Another cancer diagnosed within the 5 years before RZ-001
- Tumour cells that have spread outside the brain (extracranial metastases)
- Current or past HIV positive status
- Poor general fitness (ECOG score above 2 or KPS below 60)
- The investigator judges that the person should not join
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adult males and females
- Histologically-confirmed grade 4 astrocytoma, GBM, per The 2021 WHO Classification of CNS Tumors
- hTERT positive expression confirmed during the screening period
- ECOG score of ≤ 2
- KPS ≥ 60
- Life expectancy ≥ 3 months
Who cannot take part
- Diagnosis of other malignant tumors within 5 years prior to RZ-001 administration
- Current or history of HIV positive
- Have extracranial metastases of the tumor cells
- Not suitable for inclusion judged by the investigator
Where in South Korea
- Gachon University Gil Medical CenterIncheon, South KoreaContact: Gachon University Gil Medical CenterTaking people
- The Catholic University of Korea, Incheon St. Mary's HospitalIncheon, South KoreaContact: The Catholic University of Korea, Incheon St. Mary's HospitalTaking people
- Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Seoul National University Bundang HospitalTaking people
- Asan Medical CenterSeoul, South KoreaContact: Asan Medical CenterTaking people
- Samsung Medical CenterSeoul, South KoreaContact: Samsung Medical CenterTaking people
- Severance Hospital, Yonsei University Health SystemSeoul, South KoreaContact: Severance Hospital, Yonsei University Health SystemTaking people
About the trial
What the trial wants to find out
This is a Phase 1/2a, open-label study to evaluate the safety, tolerability, immunogenicity, and preliminary clinical activity of RZ-001 administered in combination with VGCV in subjects with hTERT-positive GBM.
The 6 groups in the trial
- Part 1 Cohort 1Treatment being tested
RZ-001 Dose 1 and VGCV
Treatment: RZ-001 and VGCV
- Part 1 Cohort 2Treatment being tested
RZ-001 Dose 2 and VGCV
Treatment: RZ-001 and VGCV
- Part 1 Cohort 3Treatment being tested
RZ-001 Dose 3 and VGCV
Treatment: RZ-001 and VGCV
- Part 1 Cohort 4Treatment being tested
RZ-001 Dose 4 and VGCV
Treatment: RZ-001 and VGCV
- Part 1 Cohort 5Treatment being tested
RZ-001 Dose 5 and VGCV
Treatment: RZ-001 and VGCV
- Part 2Treatment being tested
RZ-001 Dose 6 and VGCV
Treatment: RZ-001 and VGCV
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/2a, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, and Efficacy of RZ-001 in Combination With Valganciclovir in Subjects With Glioblastoma
- Plain-language title
- Tests RZ-001 with valganciclovir in adults with glioblastomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 5 September 2025